Clinical Trial Update: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

Phase 3 trial update investigating adverse events and disease activity changes with oral upadacitinib in adults with moderate to severe systemic lupus erythemat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: ACTIVE_NOT_RECRUITING